Navigation Links
Neurologix Announces Second Quarter 2011 Financial Results
Date:8/11/2011

gational gene therapy agent for the treatment of Parkinson's disease, and is on track to submit a Phase 3 protocol to the U.S. Food and Drug Administration under a Special Protocol Assessment later in 2011. In the second quarter of this year the Company also initiated the open-label arm of the Company's successful Phase 2 trial of NLX-P101. To date, several patients who participated in our Phase 2 trial for NLX-P101 and received sham surgery have been treated with NLX-P101 in the open-label arm of the Phase 2 trial. The Phase 2 open-label arm was initiated based on the strong efficacy results demonstrated in the randomized Phase 2 trial of NLX-P101, which included one-year follow-up data demonstrating that NLX-P101 provided treated patients with sustained long-term clinical benefits."

About NeurologixNeurologix, Inc. (OTCBB:NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix's therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company's current focus addresses Parkinson's disease, a large market not adequately served by current therapeutic options. For more information, please visit the Neurologix website at http://www.neurologix.net.

Cautionary Statement Regarding Forward-Looking StatementsThis news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information re
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
2. Bion Announces New U.S. Patent for Phosphorus Removal
3. ViaCyte Announces Executive Management Changes
4. NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis
5. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
6. Osteologix Announces Completion of Corporate Consolidation
7. Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results
8. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
9. Rigel Announces Second Quarter 2011 Financial Results
10. WAVi Co. Announces Collaborative Agreement with SomaLogic, Inc.
11. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 GraphDB™ 6.0 ... including improvements to the enterprise replication cluster, faster ... Lucene, SOLR and Elasticsearch. This release happens to ... performance triplestore – GraphDB™ was formerly known as ... the only mature enterprise resilient RDF triplestore will ...
(Date:8/19/2014)... Md. (PRWEB) August 19, 2014 ... liquid chromatography systems, Prominence-i and Nexera-i, adding to ... systems. Combining excellent functionality, an intuitive operating environment, ... and a more efficient workflow for conventional to ... feature innovative, intuitive and intelligent design so users ...
(Date:8/19/2014)... 19, 2014 A Geisinger researcher on a ... a Centers for Disease Control and Prevention (CDC) award ... health concern. Joseph Boscarino , Ph.D. ... a team of researchers nominated for the Centers for ... Award for Data Methods and Study Design. ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... Oxide Fuel Cells (SOFCs) - Global Strategic Business Report" ... the worldwide markets for Solid Oxide Fuel Cells (SOFCs) in ... US, Canada , Europe ... Annual estimates and forecasts are provided for the period 2012 ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... International Daleco Corporation (Pink Sheets: ILDO) announces its ... joint venture company, ICAP Bio Organic, S. de R.L. ... and proprietary bio-organic catalyst compositions (BOCs) within Central America, Mexico ... renewable energy credit opportunities where available. , SIF ICAP ...
... , BEIJING, Oct. 27 /PRNewswire-Asia/ ... provider of biopharmaceutical products in China, announced today that,it ... vaccine, PANFLU.1, from,China,s Ministry of Industry and Information Technology ... is required to produce an,additional 5.19 million doses of ...
... YORK, Oct. 26 Reportlinker.com announces ... is available in its catalogue. , ... Pipeline Analysis and Competitive Assessment ... , In the nearly 35 ...
Cached Biology Technology:Bio-Organic Catalyst, Inc. Forms Joint Venture With SIF ICAP Mexico S.A. de C.V. as Exclusive Distribution Hub for Central America, Mexico and Caribbean. 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 2Sinovac Obtains Third H1N1 Vaccine Order from Chinese Central Government 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 2Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 3Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 4Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 5Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 6Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 7Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment 8
(Date:8/20/2014)... of the Para and Mato Grosso states of Brazil. ... in order to deforest the land. Deforestation is the ... the land is thereafter converted to a nonforest use. ... ranches, or urban use. The herringbone-patterned tan lines cutting ... the middle of the image are evidence of deforestation ...
(Date:8/20/2014)... are athletes who have suffered concussions ready to return ... found that high school athletes who head back on ... a significant regression in their abilities to simultaneously walk ... seen in changes in their balance and/or altered walking ... of the 12 had returned to activity in less ...
(Date:8/20/2014)... DENVER (August 20, 2014) Women who are poor ... to infants with elevated levels of the stress hormone, ... later in life, according to a new research from ... online recently in the American Journal of Human ... infants and relate it directly to the socioeconomic status ...
Breaking Biology News(10 mins):Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3CU Denver researcher shows economic disparities impact infant health 2
... The Wildlife Conservation Society has launched an ambitious new program ... in key areas over the next decade, according to an ... called "Tigers Forever," blends a business model with hard science, ... have pledged an initial $10 million to support it. , ...
... has developed a remarkable nanostructured material that can repel pests ... used as a timed drug delivery system –as a nasal ... Washington University James S. McDonnell Distinguished University Professor in Arts ... developed more than four years ago as marine "antifouling" coatings ...
... study shows that statins, which are typically used as ... C virus (HCV). They could replace ribavirin in combination ... July 2006 issue of Hepatology, the official journal of ... (AASLD). Published by John Wiley & Sons, Inc., Hepatology ...
Cached Biology News:Tigers get a business plan 2Triple threat polymer captures and releases 2Triple threat polymer captures and releases 3Triple threat polymer captures and releases 4Statins stop hepatitis C virus from replicating 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
... refrigerated multifunction centrifuges are equally capable of high ... sound level with a large range of rotors ... exchange system without tools ensures that the required ... Instant rotor exchange (5 sec.) with ...
versican (H-56)...
... presents PsiPort Mass Directed Auto Purification ... data acquisition system designed for automated ... life science and pharmaceutical discovery programs. ... to simplify high throughput mass directed ...
Biology Products: